Quantitative evaluation of skeletal tumours with dynamic FDG PET: SUV in comparison to Patlak analysis
- PMID: 11440030
- DOI: 10.1007/s002590100511
Quantitative evaluation of skeletal tumours with dynamic FDG PET: SUV in comparison to Patlak analysis
Abstract
This study was carried out to evaluate bone lesions using fluorine-18 fluorodeoxyglucose positron emission tomography (FDG PET) and to explore whether dynamic and quantitative PET data may help to differentiate benign lesions from malignant masses. Forty patients with primary bone lesions were studied. The final diagnosis was confirmed by histopathology. A 60-min dynamic FDG PET acquisition was undertaken in all subjects. From the dynamic PET images, indices such as the average and maximal standardised uptake values (SUVs), the tumour SUV-to-muscle SUV ratio (T/M) and the SUV at 60 min-to-SUV at 30 min ratio (averSUV60/30 min and maxSUV60/30 min) were produced. Patlak graphical analysis was used to obtain the influx constant (Ki), and the metabolic rate of FDG (MRFDG) was calculated. Based on the receiver operator characteristic curve, the sensitivity and specificity for each parameter in differentiating between malignant and benign lesions were evaluated. The histological results revealed 21 malignant tumours and 19 benign lesions in this group. The MRFDG and SUV indices in malignant lesions were significantly higher than those in benign lesions. However, each index showed a considerable overlap between benign and malignant lesions. Average SUV correlated positively with MRFDG (r=0.67). When a cut-off of 1.8 average SUV was used, the sensitivity and specificity for discrimination of malignancy from benign disease were 85% and 82.4%, respectively. MRFDG showed a similar sensitivity (82.4%) and a better specificity (92.9%). A combination consisting of a cut-off of average SUV (1.8) and averSUV60/30 min (1.1) resulted in an improvement of specificity to 93.3%, with a small reduction in sensitivity (81.3%) as compared with exclusive use of SUV. The results of this study indicate that a detectable difference in glucose metabolism exists between malignant and benign skeletal lesions. The static FDG uptake indices alone may not enable adequate differentiation between benign and malignant lesions. Quantitative dynamic imaging may provide more helpful information, but will not permit a definite diagnosis. The use of uptake indices may represent an alternative and interesting approach to the evaluation of bone lesions.
Similar articles
-
Dual-time point PET/CT with F-18 FDG for the differentiation of malignant and benign bone lesions.Skeletal Radiol. 2009 May;38(5):451-8. doi: 10.1007/s00256-008-0643-0. Epub 2009 Feb 10. Skeletal Radiol. 2009. PMID: 19205695
-
The clinical efficacy of (18)F-FDG-PET/CT in benign and malignant musculoskeletal tumors.Ann Nucl Med. 2008 Aug;22(7):603-9. doi: 10.1007/s12149-008-0151-2. Epub 2008 Aug 29. Ann Nucl Med. 2008. PMID: 18756363
-
PET imaging of musculoskeletal tumours with fluorine-18 alpha-methyltyrosine: comparison with fluorine-18 fluorodeoxyglucose PET.Eur J Nucl Med. 2000 Oct;27(10):1509-17. doi: 10.1007/s002590000344. Eur J Nucl Med. 2000. PMID: 11083540
-
Dual-time point 18F-FDG-PET and PET/CT for Differentiating Benign From Malignant Musculoskeletal Lesions: Opportunities and Limitations.Semin Nucl Med. 2017 Jul;47(4):373-391. doi: 10.1053/j.semnuclmed.2017.02.009. Epub 2017 Apr 19. Semin Nucl Med. 2017. PMID: 28583277 Review.
-
Quantitative assessment of tumor metabolism using FDG-PET imaging.Nucl Med Biol. 2000 Oct;27(7):683-7. doi: 10.1016/s0969-8051(00)00141-4. Nucl Med Biol. 2000. PMID: 11091112 Review.
Cited by
-
Use of positron emission tomography in anticancer drug development.Invest New Drugs. 2003 May;21(2):169-81. doi: 10.1023/a:1023521412787. Invest New Drugs. 2003. PMID: 12889738 Review.
-
Differentiation between malignant and benign pathologic fractures with F-18-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography.Skeletal Radiol. 2008 May;37(5):415-21. doi: 10.1007/s00256-008-0462-3. Epub 2008 Feb 29. Skeletal Radiol. 2008. PMID: 18309481
-
Noninvasive assessment and quantification of tumor vascularization using [18F]FDG-PET/CT and CE-CT in a tumor model with modifiable angiogenesis-an animal experimental prospective cohort study.EJNMMI Res. 2019 Jun 21;9(1):55. doi: 10.1186/s13550-019-0502-0. EJNMMI Res. 2019. PMID: 31227938 Free PMC article.
-
The Potential Benefit by Application of Kinetic Analysis of PET in the Clinical Oncology.ISRN Oncol. 2012;2012:349351. doi: 10.5402/2012/349351. Epub 2012 Dec 26. ISRN Oncol. 2012. PMID: 23326682 Free PMC article.
-
Glucose corrected standardized uptake value (SUVgluc) in the evaluation of brain lesions with 18F-FDG PET.Eur J Nucl Med Mol Imaging. 2013 Jul;40(7):997-1004. doi: 10.1007/s00259-013-2396-9. Epub 2013 Apr 10. Eur J Nucl Med Mol Imaging. 2013. PMID: 23571761
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical